Goldman Sachs Group Analysts Give Merck KGaA (MRK) a €100.00 Price Target
Goldman Sachs Group set a €100.00 ($119.05) price objective on Merck KGaA (FRA:MRK) in a research report released on Wednesday morning. The brokerage currently has a neutral rating on the healthcare company’s stock.
Other equities analysts have also recently issued research reports about the stock. J P Morgan Chase & Co set a €100.00 ($119.05) target price on shares of Merck KGaA and gave the company a neutral rating in a research note on Friday, October 6th. Citigroup set a €123.00 ($146.43) target price on shares of Merck KGaA and gave the company a buy rating in a research note on Monday, September 25th. Oddo Bhf set a €125.00 ($148.81) target price on shares of Merck KGaA and gave the company a buy rating in a research note on Friday, November 10th. Kepler Capital Markets set a €119.00 ($141.67) target price on shares of Merck KGaA and gave the company a buy rating in a research note on Thursday, September 21st. Finally, Deutsche Bank set a €99.00 ($117.86) target price on shares of Merck KGaA and gave the company a neutral rating in a research note on Friday, November 10th. Eleven research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. The company has a consensus rating of Buy and an average price target of €108.52 ($129.20).
Shares of Merck KGaA (MRK) opened at €89.39 ($106.42) on Wednesday. Merck KGaA has a twelve month low of €87.99 ($104.75) and a twelve month high of €115.00 ($136.90).
TRADEMARK VIOLATION NOTICE: This article was first published by Watch List News and is owned by of Watch List News. If you are accessing this article on another domain, it was illegally stolen and reposted in violation of international copyright law. The original version of this article can be read at https://www.watchlistnews.com/goldman-sachs-group-analysts-give-merck-kgaa-mrk-a-100-00-price-target/1740445.html.
About Merck KGaA
MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with Analyst Ratings Network's FREE daily email newsletter.